Geneva, Feb. 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119069) titled 'A retrospective study on the efficacy and safety of yttrium-90 versus conventional transcatheter arterial chemoembolization (TACE) combined with target immunotherapy in the treatment of unresectable hepatocellular carcinoma' on Feb. 14.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The First Affiliated Hospital of Army Medical University
Condition:
hepatocellular carcinoma (HCC)
Intervention:
Single yttrium-90 treatment group:None
TACE combined with target therapy and timmunotherapy group:None
Single TACE group treatment group:None
Recruitment Status: Not Recruiting
Phase: ...